Rituxan (Systemic Lupus Erythematosus and Lupus Nephritis) - Forecast and Market Analysis to 2022
Systemic lupus erythematosus (SLE) is a systemic inflammatory autoimmune disease that can affect any organ or tissue and is the prototypic autoimmune disease. While SLE can affect multiple major organ systems in the body, one of its most severe manifestations includes renal (kidney) involvement, known as lupus nephritis (LN). The term LN refers to SLE patients with glomerulonephritis, and when the term LN is used, glomerular tissue injury in the kidneys is always involved. Renal injury without any glomerular involvement is classified as nephritis in a patient with SLE.
Rituxan is a monoclonal antibody that binds to the transmembrane antigen CD20 expressed on B-cells. Its binding to B-cells mediates their apoptotic death and depletion. Rituxan was initially developed for the treatment of non-Hodgkin's lymphoma and subsequently gained marketing approvals for use in RA, chronic lymphocytic leukemia (CLL) and granulomatosis (Roche, 2013).
Overview of SLE-LN, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
Detailed information on Rituxan including product description, safety and efficacy profiles as well as a SWOT analysis.
Sales forecast for Rituxan for the top seven countries from 2012 to 2022.
Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan
Reasons to buy
Understand and capitalize by identifying products that are most likely to ensure a robust return
Stay ahead of the competition by understanding the changing competitive landscape for SLE-LN
Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
Make more informed business decisions from insightful and in-depth analysis of Rituxan performance
Obtain sales forecast for Rituxan from 2012-2022 in top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan)